EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (CLANC)
Nasopharyngeal Cancer, EBV Infections
About this trial
This is an interventional treatment trial for Nasopharyngeal Cancer focused on measuring EBV, NASOPHARYNGEAL, CARCINOMA, EBV POSITIVE NASOPHARYNGEAL CARCINOMA
Eligibility Criteria
Inclusion Criteria: Any patient with EBV positive NPC, in relapse or with primary resistant disease Life expectancy of more than 6 weeks. No severe intercurrent infection Patient, parent/guardian able to give informed consent Bilirubin less than 2x normal SGOT less than 3x normal, Hgb higher than 8.0 g/L Creatinine less than 2x normal for age Patients should have been off other investigational therapy for one month prior to entry in this study. Karnofsky score of over or equal to 50. Exclusion Criteria: Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator's discretion after approval by the CCGT Protocol Review Committee and the FDA reviewer. .
Sites / Locations
- Texas Children's Hospital
- The Methodist Hospital